C. Fernández-Díaz
A5058844953- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Vasculitis and related conditions
- Sarcoidosis and Beryllium Toxicity Research
- Ocular Diseases and Behçet’s Syndrome
- Spondyloarthritis Studies and Treatments
- Urticaria and Related Conditions
- Autoimmune and Inflammatory Disorders Research
- Retinal and Optic Conditions
- Psoriasis: Treatment and Pathogenesis
- Renal Diseases and Glomerulopathies
- Otitis Media and Relapsing Polychondritis
- SARS-CoV-2 and COVID-19 Research
- Oral Health Pathology and Treatment
- Inflammatory Myopathies and Dermatomyositis
- Bone and Joint Diseases
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Atherosclerosis and Cardiovascular Diseases
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Bone Metabolism and Diseases
- Long-Term Effects of COVID-19
- Immunodeficiency and Autoimmune Disorders
Hospital Reina Sofía de Murcia
2023-2024
Santa Lucía University General Hospital
2024
Hospital Universitario Reina Sofía
2023-2024
Hospital Universitario de Gran Canaria Doctor Negrín
2022
Marqués de Valdecilla University Hospital
2017-2021
Hospital Universitario de La Princesa
2020-2021
Instituto de Investigación Marqués de Valdecilla
2016-2021
Universidad de Cantabria
2018-2021
Hospital Universitario del Vinalopó
2019
Research Institute Hospital 12 de Octubre
2018
BackgroundPatients with coronavirus disaese 2019 (COVID-19) can develop a cytokine release syndrome that eventually leads to acute respiratory distress requiring invasive mechanical ventilation (IMV). Because IL-6 is relevant in syndrome, the blockade of its receptor tocilizumab (TCZ) could reduce mortality and/or morbidity severe COVID-19.ObjectiveWe sought determine whether baseline serum levels predict need for IMV and response TCZ.MethodsA retrospective observational study was performed...
To assess the efficacy of tocilizumab (TCZ) in refractory uveitis Behçet's disease (BD).Multicentre study patients with BD-associated uveitis. Patients were to conventional and biologic immunosuppressive drugs. The main outcome measures intraocular inflammation, macular thickness, visual acuity corticosteroid-sparing effects.We studied 11 (7 men) (20 affected eyes); median age 35 years. Uveitis was bilateral nine patients. patterns ocular involvement panuveitis (n = 8, retinal vasculitis 4),...
Abstract Objective To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods This was an observational, multicentre study RA-ILD treated at least one dose ABA. ILD diagnosed by high-resolution CT (HRCT). We analysed following variables baseline (ABA initiation), 12 months and end follow-up: Modified Medical Research Council (MMRC) scale (1-point change), forced vital capacity (FVC) or diffusion for carbon monoxide (DLCO) (improvement...
To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABAMONO) vs combined ABA [ABA plus MTX (ABAMTX) or non-MTX conventional synthetic DMARDs (csDMARDs) (ABANON-MTX)] RA patients with interstitial lung disease (ILD) (RA-ILD).This was a restrospective multicentre study RA-ILD Caucasian treated ABA. We analysed three groups (ABAMONO, ABAMTX, ABANON-MTX) following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) diffusion for carbon monoxide (DLCO); (iii) chest...
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) clinical practice. Methods: A multicenter study TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement imaging techniques, adverse events. comparative between TCZ as monotherapy (TCZ MONO ) combined conventional disease modifying anti-rheumatic drugs (cDMARDs) COMBO was performed. Results: comprised 54 (46 women/8...
<h3>Background:</h3> Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment RA-ILD, regardless combined or not with methotrexate and radiological pattern <b>[1-3].</b> Although global results are satisfactory, there patients who present progression ILD despite its use. The characterization this group crucial for early identification management <h3>Objectives:</h3> To assess a)...
Background: Tocilizumab (TCZ) was recently approved for Takayasu Arteritis (TAK) in Japan based on the results of TAKT trial (1). However, data clinical practice Europe and America are scarce (2). Objectives: To assess efficacy safety TCZ TAK Spain. Methods: Observational, open-label multicentre study 53 patients treated with due to refractoriness or adverse events previous therapy. Outcomes variables were improvement features, acute phase reactants glucocorticoid-sparing effect. Results:...
<h3>Background</h3> Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA). AntiTNFα drugs and conventional disease-modifying anti-rheumatic (DMARDs) such as methotrexate (MTX) have been involved in the development ILD. IL6 has implicated pathogenesis ILD (Kobayashi J et al). However, fatal case exacerbation described with tocilizumab (TCZ) (Kawashiri SY el at). <h3>Objectives</h3> Our aim was to assess efficacy safety TCZ associated AR....
<h3>Background:</h3> Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment RA-ILD <b>[1-2].</b> <h3>Objectives:</h3> To compare ABA patients according to ILD duration. <h3>Methods:</h3> National multicenter study 526 treated with ABA. Patients initiation early (during first 6 months since diagnosis) were compared those whom was started after 2 years diagnosis ("early" vs. "late" group, respectively)....
<h3>Background:</h3> TNF alpha inhibitors (anti-TNFα) have demonstrated their efficacy and safety in the treatment of patients with spondyloarthritis (SpA) high response survival rates first line (1). Currently, new recommendations on SpA indicate that if a first-line anti-TNFα is ineffective, it can be switched to an anti-IL17 or another molecule (1)(2)(3). It seems this switch second does not decrease such <h3>Objectives:</h3> To analyze whether presenting primary failure associated when...
<h3>Background</h3> Anti-TNFα drugs and several conventional disease-modifying anti-rheumatic (DMARDs) such as methotrexate (MTX) have been involved in the development of Interstitial Lung Disease (ILD). <h3>Objectives</h3> Our aim was to assess efficacy safety Rituximab (RTX) RA patients with ILD. <h3>Methods</h3> Multicenter study ILD treated RTX. diagnosed by high-resolution computed tomography (HRCT). RTX used at standard dose (1 gx2 premedication iv Methylprednisolone for a six month...
<h3>Background</h3> Interstitial lung disease (ILD) associated with Rheumatoid Arthritis (RA) has a poor prognosis. Treatments such as anti-TNF, have been implicated in the exacerbation of an ILD. <h3>Objectives</h3> Our objective is to evaluate and compare evolution ILD patients RA treated Abatacept (ABA), Rituximab (RTX) Tocilizumab (TCZ) after 1 year treatment. <h3>Methods</h3> Retrospective multicentre study AR ABA, RTX TCZ at standard doses. The was diagnosed by CT. efficacy evaluated...
Background: Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA). In this line, several radiological patterns RA-ILD have been described: i) usual interstitial pneumonia (UIP), ii) nonspecific (NSIP), iii) obliterating bronchiolitis, iv) organized and mixed patterns. Abatacept (ABA) could be an effective safe option for patients with RA-ILD, although the response in different not well defined. Objectives: Our aim was to assess ABA ILD....
<h3>Background</h3> Non-infectious aortitis is often an underrecognised condition. Early diagnosis and treatment crucial to prevent serious complications. Corticosteroids represent the first-line therapy of non-infectious aortitis. However, disease-modifying antirheumatic drugs (DMARDS) and/or biologic are usually required. <h3>Objectives</h3> Our aim was assess outcome patients diagnosed with from a single centre. <h3>Methods</h3> Retrospective study 32 (22 women/10 men) based on imaging...
<h3>Background</h3> Disease modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX), leflunomide (LFN) or antiTNFα have been implicated in development/exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis (RA). Several radiological patterns ILD described: i) usual interstitial pneumonia (UIP), ii) nonspecific (NSIP), iii) obliterating bronchitis (OB), and iv) Organized (OP) <h3>Objectives</h3> To assess the response to Abatacept (ABA) these <h3>Methods</h3>...
<h3>Objectives</h3> To assess the long term efficacy and optimization of Infliximab (IFX) in refractory Uveitis Behçet Disease (BD) <h3>Methods</h3> Multicentre study associated-BD to conventional immunosupressive drug. Ocular inflammation was evaluated with "SUN criteria" (Am J Ophthalmol 2005;140:509–516) macular thickening OCT. Results are expressed as mean±SD or median [IQR] (comparison, Wilcoxon test) <h3>Results</h3> We studied 100 patients/180 affected eyes (54M/46W), mean age...
<h3>Background</h3> Uveitis is a severe manifestation of Juvenil Idiopathic Arthritis (JIA). Anti-TNFa are recommended in refractory cases, mainly infliximab (IFX) or adalimumab (ADA) (Levy-Clarke et al. Ophthalmology 2014; 121: 785–796). However, sometimes they ineffective, contraindicated not tolerated. The next therapeutic step defined. <h3>Objectives</h3> To compare the efficacy Golimumab (GLM) and Tocilizumab (TCZ) related AIJ uveitis to conventional immunosuppressive drugs anti-TNFα....